Benjamin P. Martin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Benjamin P. Martin has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ricky W. Johnstone
The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia
21 shared publications - Belinda Maher
Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia
20 shared publications - Cheng Mun Wun
Peter MacCallum Cancer Centre, Melbourne, Australia
20 shared publications - Daniella Brasacchio
Blood Cancer Therapeutics Laboratory, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia
20 shared publications - Emily Gruber
Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3010, Australia
20 shared publications - Gisela Mir Arnau
Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
20 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF17
Sensitivity of Pancreatic Adenocarcinoma Cells to Blockade of Post-initiation CDK-Dependent Pol II Transcription Cycle Checkpoints
Pancreatic adenocarcinoma (PDAC) is a leading cause of cancer-related morbidity, with oncogenic KRAS/MAPK/ERK signaling arising from activating KRAS mutations being the key feature of this malignancy. Dysregulation of RNA polymerase II (Pol II)–dependent transcription is a universal hallmark of cancers, including PDAC, with aberrant gene expression programs driving tumorigenesis and influencing therapy response. Pol II progression through multiple transcription cycle checkpoints depends on transcriptional cyclin-dependent kinases (tCDK), and targeted inhibition of distinct tCDKs has been shown to be a promising anticancer strategy. In this study, we profile biological and molecular PDAC cell responses to selective blockade of tCDK kinase activity at all Pol II transcription cycle checkpoints, alone and in combination with inhibitors of mutant KRAS or MEK. We identify post–transcription-initiation checkpoints controlled by CDK9, CDK11, and CDK12/13 as critical for nascent gene expression and cell proliferation in PDAC. However, although dual targeting of tCDK and KRAS/MAPK/ERK networks amplifies transcriptomic phenotypes, this results in limited cooperative therapeutic impacts.
- 30 September 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF17
Open AccessSensitivity of Pancreatic Adenocarcinoma Cells to Blockade of Post-initiation CDK-Dependent Pol II Transcription Cycle Checkpoints
Pancreatic adenocarcinoma (PDAC) is a leading cause of cancer-related morbidity, with oncogenic KRAS/MAPK/ERK signaling arising from activating KRAS mutations being the key feature of this malignancy. Dysregulation of RNA polymerase II (Pol II)–dependent transcription is a universal hallmark of cancers, including PDAC, with aberrant gene expression programs driving tumorigenesis and influencing therapy response. Pol II progression through multiple transcription cycle checkpoints depends on transcriptional cyclin-dependent kinases (tCDK), and targeted inhibition of distinct tCDKs has been shown to be a promising anticancer strategy. In this study, we profile biological and molecular PDAC cell responses to selective blockade of tCDK kinase activity at all Pol II transcription cycle checkpoints, alone and in combination with inhibitors of mutant KRAS or MEK. We identify post–transcription-initiation checkpoints controlled by CDK9, CDK11, and CDK12/13 as critical for nascent gene expression and cell proliferation in PDAC. However, although dual targeting of tCDK and KRAS/MAPK/ERK networks amplifies transcriptomic phenotypes, this results in limited cooperative therapeutic impacts.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
(A) Representative FACS gating strategy for tracking cell-cycle in JJN3 cells. (B) Percentage of JJN3 cells within sub-G1 phase (n = 3). Error bars represent mean. +/- SEM. (C) Percentage viability of JJN3 cells treated with VPR8 and/or QVD. Error bars represent mean +/- SD (n = 3). (D) Time spent in each phase of cell cycle, quantifying kinetics of JJN3-PIP-FUCCI cells. Each circle represents an individual cell, n = 2 biological replicates. Error bars represent median +/- 95% confidence interval. Significance calculated using Mann-Whitney t-test, with measurements from individual cells pooled from 2 independent experiments (**** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05).
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
(A) Representative FACS gating strategy for tracking cell-cycle in JJN3 cells. (B) Percentage of JJN3 cells within sub-G1 phase (n = 3). Error bars represent mean. +/- SEM. (C) Percentage viability of JJN3 cells treated with VPR8 and/or QVD. Error bars represent mean +/- SD (n = 3). (D) Time spent in each phase of cell cycle, quantifying kinetics of JJN3-PIP-FUCCI cells. Each circle represents an individual cell, n = 2 biological replicates. Error bars represent median +/- 95% confidence interval. Significance calculated using Mann-Whitney t-test, with measurements from individual cells pooled from 2 independent experiments (**** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05).
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Movie S3 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of DU145-eGFP-tubulin cells treated with DMSO, undergoing mitotic spindle formation and cytokinesis. Time (hr:min).
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie S3 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of DU145-eGFP-tubulin cells treated with DMSO, undergoing mitotic spindle formation and cytokinesis. Time (hr:min).
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data File 1 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Drug Synthesis pathway, Supplementary movie legends
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data File 1 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Drug Synthesis pathway, Supplementary movie legends
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Movie S2 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of JJN3-PIP-FUCCI cells treated with 500nM VPR8, showing a cell that is mitotic but doesn't undergo cytokinesis (dark blue arrowhead), or a cell that is mitotic and dies (pink arrowhead). Mitotic phases indicated by colours as follows: green (G1), yellow (G2M), red (S). Time (hr:min).
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie S2 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of JJN3-PIP-FUCCI cells treated with 500nM VPR8, showing a cell that is mitotic but doesn't undergo cytokinesis (dark blue arrowhead), or a cell that is mitotic and dies (pink arrowhead). Mitotic phases indicated by colours as follows: green (G1), yellow (G2M), red (S). Time (hr:min).
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Putative DCAFs used for myeloma loss of representation screen
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Putative DCAFs used for myeloma loss of representation screen
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
(A) Correlation of DepMap gene effect dependency score and percentage inhibition by VPR8 for the targets that showed >50% inhibition by VPR8. (B-C) RNAseq of JJN3 cells treated with B32B3 or VPR8 for 6 and 24h. (B) Volcano plot and number of differentially expressed genes (p < 0.01 & |logFC| > 0.5). (C) Heatmap of the union of VPR8 and B32B3 differentially expressed genes (DEGs) at 24 hr. (D-E) Number of differential phosphopeptides and proteins. (F) Heatmap of the proteins that are differentially expressed following 24hr VPR8 treatment.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
(A) Correlation of DepMap gene effect dependency score and percentage inhibition by VPR8 for the targets that showed >50% inhibition by VPR8. (B-C) RNAseq of JJN3 cells treated with B32B3 or VPR8 for 6 and 24h. (B) Volcano plot and number of differentially expressed genes (p < 0.01 & |logFC| > 0.5). (C) Heatmap of the union of VPR8 and B32B3 differentially expressed genes (DEGs) at 24 hr. (D-E) Number of differential phosphopeptides and proteins. (F) Heatmap of the proteins that are differentially expressed following 24hr VPR8 treatment.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Movie S4 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of DU145-eGFP-tubulin cells treated with 1µM VPR8, displaying microtubule disruption and abnormal spindle formation. Time (hr:min).
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie S4 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of DU145-eGFP-tubulin cells treated with 1µM VPR8, displaying microtubule disruption and abnormal spindle formation. Time (hr:min).
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Movie S1 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of JJN3-PIP-FUCCI cell (indicated with light blue arrowhead) treated with DMSO, undergoing mitosis and cytokinesis. Mitotic phases indicated by colours as follows: green (G1), yellow (G2M), red (S). Time (hr:min)
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie S1 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of JJN3-PIP-FUCCI cell (indicated with light blue arrowhead) treated with DMSO, undergoing mitosis and cytokinesis. Mitotic phases indicated by colours as follows: green (G1), yellow (G2M), red (S). Time (hr:min)
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Supplementary Table S5 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Supplementary Table S5 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity